Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2025 08:00 ET | Source: Rivus Pharmaceuticals, Inc.

Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025

Phase 2 M-ACCEL trial in MASH met primary endpoint, with statistically significant reductions in liver fat observed in all HU6 treatment groups